Daily Anesthesiology Research Analysis
Analyzed 94 papers and selected 3 impactful papers.
Summary
Three impactful advances span perioperative organ protection, cardiac surgical arrhythmia management, and sustainability in anesthesia. An IPD meta-analysis shows that guideline-based kidney protection strategies in biomarker-enriched high-risk surgical patients substantially reduce moderate-to-severe AKI. New STS guidelines standardize prevention and treatment of postoperative atrial fibrillation, while a scoping review outlines practical, high-yield carbon-reduction strategies in anesthesia without compromising safety.
Research Themes
- Perioperative organ protection and AKI prevention
- Cardiac surgery postoperative atrial fibrillation management
- Sustainable anesthesia and carbon reduction strategies
Selected Articles
1. Implementation of a kidney protection strategy to prevent acute kidney injury after major surgery in high-risk patients identified by biomarkers: a systematic review and individual participant data meta-analysis of randomized controlled trials.
Across four RCTs (n=1,851), a KDIGO-based kidney protection bundle in biomarker-enriched high-risk surgical patients reduced moderate-to-severe AKI within 72 h (OR 0.55, 95% CI 0.44–0.70) with no evidence of heterogeneity. The strategy integrated hemodynamic optimization, nephrotoxin avoidance, renal function monitoring, and glycemic control.
Impact: Provides high-level evidence that a standardized kidney protection bundle meaningfully reduces clinically significant AKI soon after major surgery in high-risk patients.
Clinical Implications: Adopting a KDIGO-based perioperative kidney protection protocol for biomarker-identified high-risk patients can reduce stage ≥2 AKI. Hospitals should integrate hemodynamic targets, nephrotoxin stewardship, frequent renal labs, and glucose control into ERAS and ICU pathways.
Key Findings
- Moderate-to-severe AKI (KDIGO stage ≥2 within 72 h) was significantly lower with the kidney protection bundle (OR 0.55, 95% CI 0.44–0.70; p<0.0001).
- No evidence of heterogeneity across included trials (non-significant heterogeneity test).
- Biomarker-enriched selection identified patients who benefited from bundle implementation; the incremental value of enrichment itself remains uncertain.
Methodological Strengths
- Individual participant data meta-analysis of randomized controlled trials with GRADE assessment
- Predefined bundle components and rigorous risk-of-bias evaluation (RoB 2.0)
Limitations
- Unclear incremental value of biomarker-guided enrichment versus universal implementation
- Potential variability in protocol adherence and bundle execution across trials
Future Directions: Conduct pragmatic, multicenter trials comparing universal versus biomarker-enriched implementation, assess long-term renal and mortality outcomes, and evaluate cost-effectiveness.
PURPOSE: Acute kidney injury (AKI) is a common complication after major surgery and is associated with increased morbidity and mortality. Kidney protection strategies may help prevent moderate or severe AKI in high-risk patients. This study aims to assess the effect of the Kidney Disease: Improving Global Outcomes (KDIGO) kidney protection strategy for the prevention of AKI in patients after major surgery. METHODS: We conducted a systematic review and individual participant data (IPD) meta-analysis of randomized controlled trials (RCTs) comparing the kidney protection strategy recommended by international guidelines consisting of hemodynamic and fluid status optimization, avoidance of nephrotoxins or radiocontrast agents, regular monitoring of kidney function, and glycemic control to standard care in high-risk patients after major surgery with an enrichment strategy based on renal biomarkers. The primary outcome was moderate or severe AKI (KDIGO stage ≥ 2) within 72 h after surgery. MEDLINE via PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from January 1, 2000, to September 1, 2025. References of eligible trials and related reviews were hand-searched. Two reviewers independently assessed trial quality using the Cochrane Risk of Bias tool version 2.0. Certainty of the evidence was assessed using GRADE. IPD were pooled. Odds ratios (ORs) and mean difference with 95% confidence intervals (CIs) were computed with one-stage IPD meta-analysis. Heterogeneity was assessed by I
2. The Society of Thoracic Surgeons 2026 Clinical Practice Guidelines for the Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation after Cardiac Surgery.
The STS 2026 guideline synthesizes evidence and issues 15 recommendations spanning prevention, intraoperative strategies, and treatment of POAF after cardiac surgery. Class I recommendations include perioperative oral amiodarone and emergent cardioversion for unstable POAF, with Class IIa support for posterior pericardiotomy and perioperative beta-blockers.
Impact: The guideline provides actionable, graded recommendations likely to standardize care and reduce practice variability in a highly prevalent and morbid postoperative complication.
Clinical Implications: Implement perioperative oral amiodarone prophylaxis in appropriate patients, consider posterior pericardiotomy and ensure perioperative beta-blockade; perform urgent cardioversion for hemodynamically unstable POAF. Tailor strategies to individual risk and side-effect profiles.
Key Findings
- Fifteen graded recommendations addressing POAF across pre-, intra-, and postoperative phases.
- Class I: perioperative oral amiodarone; emergent rhythm cardioversion for unstable POAF.
- Class IIa: posterior pericardiotomy and perioperative beta-blockers; several areas remain Class IIb reflecting limited data.
Methodological Strengths
- Standardized guideline development using PICO, graded by Class of Recommendation and Level of Evidence
- Multidisciplinary authorship and comprehensive synthesis of RCTs and observational studies
Limitations
- Heterogeneous and sometimes limited quality of evidence, with many Class IIb recommendations
- Uncertainties in optimal dosing/timing for pharmacologic strategies and evolving intraoperative techniques
Future Directions: Randomized trials to refine dosing and timing of amiodarone/beta-blockers, evaluate posterior pericardiotomy across risk strata, and develop risk-prediction tools to personalize POAF prevention.
BACKGROUND: Postoperative atrial fibrillation (POAF) is the most frequent complication after cardiac surgery and is associated with greater morbidity, mortality, length of stay, and cost. Multiple pharmacologic and procedural strategies exist for POAF prevention and treatment, yet practice variation persists. The Society of Thoracic Surgeons (STS) Workforce on Evidence-Based Surgery convened a multidisciplinary writing group to synthesize contemporary evidence and develop guideline recommendations for preventing and treating new-onset POAF after cardiac surgery. METHODS: In 2025, the group used the Population, Intervention, Comparison, Outcome framework to formulate clinical questions spanning preoperative, intraoperative, and postoperative domains. Following standardized STS methodology, evidence from randomized controlled trials and observational studies was reviewed, and recommendations were graded by Class of Recommendation and Level of Evidence. RESULTS: Fifteen recommendations were developed: 8 addressing preventive strategies, 3 intraoperative techniques, and 4 postoperative treatments. Two Class I recommendations addressed perioperative oral amiodarone and rhythm cardioversion for hemodynamically unstable POAF. Two Class IIa recommendations supported posterior pericardiotomy and perioperative beta-blockers. Eight Class IIb recommendations reflected areas of uncertainty and limited data. Three Class III recommendations addressed therapies without demonstrated benefit. CONCLUSIONS: Levels of evidence vary across interventions, and high-quality data remain limited for POAF after cardiac surgery. Pharmacologic studies often lack granularity in dose and timing, and intraoperative maneuvers continue to evolve. Individualized risk assessment remains essential given therapy-related side effects. The 2026 STS guidelines provide the most comprehensive recommendations focused on postoperative atrial fibrillation after cardiac surgery, offering a framework to standardize care and highlight future investigational priorities.
3. Sustainable Anesthesia: A Scoping Review of Carbon Reduction Strategies.
This PRISMA/PRESS-conformant scoping review synthesized 33 studies evaluating interventions to reduce anesthesia-related CO2e. Strategies such as eliminating desflurane, restricting nitrous oxide, promoting TIVA/regional anesthesia, low fresh gas flows, equipment reuse, waste reduction, telemedicine, and education achieved 50–90% CO2e reductions without compromising safety.
Impact: Provides a consolidated, practical framework of high-yield sustainability interventions for anesthesia services, supporting immediate, system-wide carbon reduction without compromising patient care.
Clinical Implications: Departments can prioritize eliminating desflurane, restricting nitrous oxide, adopting TIVA/regional techniques when appropriate, optimizing fresh gas flows, and instituting reuse/waste reduction programs with education and monitoring to achieve substantial CO2e reductions.
Key Findings
- Across 33 studies, reported CO2e reductions ranged from 50% to >90% with combined technical, behavioral, and organizational measures.
- High-impact levers included eliminating desflurane, restricting nitrous oxide, promoting TIVA/regional anesthesia, and optimizing fresh gas flows.
- No evidence of compromised patient safety across included interventions; several studies reported absolute savings of multiple tonnes CO2e per year.
Methodological Strengths
- PRISMA/PRESS-conformant scoping methodology with dual independent screening and MMAT quality appraisal
- Inclusive synthesis across multiple countries and intervention types enabling generalizable operational insights
Limitations
- Heterogeneity in intervention types, measurement methods, and contexts limits quantitative pooling and causal inference
- Several included studies were observational with variable quality; five were rated low quality
Future Directions: Prospective, multicenter implementation studies with standardized CO2e reporting and patient outcomes, plus life-cycle assessments to optimize equipment reuse and supply chains.
Anesthesia contributes substantially to healthcare-related greenhouse gas (GHG) emissions especially by inhalational agents such as desflurane, sevoflurane, nitrous oxide, relying on single-use equipment and having high energy demand equipment. Over the past decade, increased awareness of these impacts has led to growing research into sustainable anesthesia, exploring interventions such as low-emission techniques, equipment reuse, waste reduction, and workflow optimization. A scoping review was conducted according to PRISMA and PRESS guidelines. The databases Embase and MEDLINE were searched for studies (2010-2025) reporting on interventions to reduce anesthesia-related carbon footprint equivalents (CO2e). Eligible studies were prospective or retrospective in human patients and reported results in CO2e. Two reviewers independently screened and extracted data. Study quality was assessed using the Mixed Methods Appraisal Tool (MMAT). Of 3309 records identified, 33 studies met the inclusion criteria and were included in the synthesis. Five studies were rated as low quality. The included studies, conducted across ten countries, evaluated diverse sustainability interventions including nitrous oxide restriction, reduction or elimination of desflurane, promotion of total intravenous or regional anesthesia, optimization of fresh gas flows, equipment reuse, waste reduction, telemedicine, and departmental educational programs. Reported outcomes showed CO2e reductions ranging from 50% to over 90%, with some interventions achieving absolute savings of several tonnes CO2e per year. Our analysis shows that various strategies, including low-emission techniques, equipment reuse, waste reduction, and telemedicine, can significantly lower anesthesia-related CO2e without compromising patient safety. The greatest impact comes from combining behavioral, technical, and organizational measures, highlighting the need for a coordinated, system-wide approach.